Founded in 1997, Vectura Group plc is a pulmonary drug development company focused principally on the development of a range of inhaled pharmaceuticals for the treatment of respiratory and neurological diseases. Vectura is based in the UK, with headquarters and development operations in Chippenham, Wiltshire, further laboratories in Nottingham, and device development in Cambridge. Vectura's shares trade on the London Stock Exchange under the symbol VEC.

Acquired Companies: Innovata